1N. D. Vaziri, Dyslipidemia of chronic renal failure: the nature, mechanisms,and potential consequences ,Am J Physiol Renal Physiol ,2006, 290: F262- F272.
2Majumdar A and Wheeler DC, Lipid abnormalities in renal disease, J R Soc Med , 2000,93:178-182.
3Schaeffner KS, Kurth T, Curhan GC, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol, 2003, 14: 2084 -2091.
4GA Kaysen,Dyslipidemia in chronic kidney disease: Causes and consequences ,Kidney International ,2006,70, S55 - S58.
5Vaziri ND,Molecular mechanisms of lipid dysregulation in nephritic syndrome, Kidney Int , 2003,63:1964-1976.
6Vaziri ND, Liang K, Azad H. Effect of cyclosporine on HMG- CoA reductase, cholesterol 7_- hydroxylase, LDL receptor, HDL receptor, VLDL receptor and lipoprotein lipase expressions. J Pharmacol Exp Ther,2000, 294:778-783.
7Kamanna VS, Low density lipoproteins and mitogenic signal transduction processes: role in the pathogenesis of renal disease. Histol Histopathol. 2002,17(2) :497 -505.
8CM Chan, MBBS, MRCP. Hyperlipidaemia in Chronic Kidney Disease, Ann Acad Med Singapore ,2005,35:31 -35.
9Vaziri ND, Dang B, Zhan CD, et al. Downregulation of hepatic acyl - CoA: diglycerol acyltransferase (DGAT) in chronic renal failure. Am J Physiol Renal Physiol, 2004,287 :P90- F94.
10Vaziri ND, Deng G, and Hang K, Hepatic HDL receptor, SR -B1 and Apo A -I expression in chronic renal failure. Nephrol Dial Transplant, 1999, 14:1462 - 1466.
